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ABSTRACT
Solitary plasmacytoma (SP) is a tumor with evidence of clonal plasma cells and no other features of multiple myeloma 
(MM). We report a case of SP which showed multiple recurrences of SP and then evolution into overt MM. A 56-year-old 
man presented with the 5-month-history of right nasal obstruction and intermittent epistaxis. He had SP (extraosseous) of 
right nasopharynx (3.5 × 2 × 2.5 cm), with no paraproteinaemia. He received radiotherapy (56 Gy), achieving complete 
remission. Ten years later, he had recurrence of  SP (osseous) in left tibia, presenting with pathological fracture. He 
received radiotherapy (50 Gy), achieving partial response. Three years later, he had recurrence of SP (osseous) in right 
tibia, presenting with right leg pain. He received radiotherapy (45 Gy). While receiving treatment, he had progressive 
swelling  in the area around right eye,  double vision and headache. Imaging scans showed multiple plasmacytomas. There 
were presence of monoclonal paraprotein, hypercalcemia and lytic bone lesions. He was diagnosed as MM (at the age 
of 70 years) and treated with Bortezomib-based therapy. Currently, after one cycle of treatment, clinical improvement is 
achieved. The importance of multi-disciplinary team approach for managing patients with plasmacytoma is highlighted 
in order to achieve the holistic approach of management. 
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ABSTRAK
Plasmasitoma bersendirian (SP) adalah tumor yang menunjukkan kewujudan  sel plasma klon dan tidak menunjukkan 
ciri-ciri mieloma multipel (MM). Kami melaporkan kes SP yang berlaku berulang kali dan kemudian berevolusi menjadi 
MM yang nyata. Seorang pesakit lelaki berusia 56 tahun mengalami halangan hidung kanan selama 5 bulan dan epistaksis 
berkala. Beliau mempunyai SP (extraosseous) di nasofarinks kanan (3.5 × 2 × 2.5 cm) dan tiada paraproteinemia. Beliau 
telah menerima rawatan radioterapi (56 Gy) dan mencapai remisi lengkap. Sepuluh tahun kemudian, beliau mengalami 
keberulangan SP (osseous) di tibia kiri dengan patah patologi. Beliau menerima radioterapi (50 Gy) dan mencapai tindak 
balas separa. Tiga tahun kemudian, beliau mengalami keberulangan SP (osseous) di tibia kanan, dengan kesakitan 
pada kaki kanan. Beliau menerima radioterapi (45 Gy). Semasa menerima rawatan, beliau mengalami pembengkakan 
progresif di kawasan mata kanan, penglihatan berganda dan sakit kepala. Pengimbasan imej menunjukkan plasmasitoma 
berbilang. Terdapat kehadiran paraprotein monoklon, hiperkalsemia  dan lesi tulang lytik. Beliau didiagnosis sebagai 
MM (pada usia 70 tahun) dan dirawat dengan terapi Bortezomib. Selepas satu kitaran rawatan, beliau menunjukkan 
peningkatan secara klinikal. Kepentingan pendekatan pelbagai disiplin dalam pengurusan pesakit plasmasitoma perlu 
difokuskan demi mencapai pendekatan pengurusan yang holistik.
Kata kunci: Gangguan proliferatif sel plasma; mieloma multipel; plasmasitoma  
INTRODUCTION
A plasmacytoma is a discrete, solitary mass of neoplastic 
monoclonal plasma cells in either bone or soft tissue. 
Solitary plasmacytoma (SP) is a rare entity of plasma cell 
proliferative disorder and is a biopsy-proven tumor with 
evidence of clonal plasma cells and no evidence of other 
features of multiple myeloma (MM). There are 2 types 
of SP as determined by the location of the lesions: SP of 
bone and solitary extramedullary plasmacytoma. Solitary 
plasmacytoma of bone (solitary osseous plasmacytoma, 
SPB) is a localized tumor in the bone and occurs most 
frequently in the vertebral column. Solitary extramedullary 
plasmacytoma (solitary extraosseous plasmacytoma, SEP) 
arises outside the bone in soft tissues and occurs most 
frequently in the head and neck region, mainly in the upper 
aerodigestive tract. Multiple plasmacytomas are defined as 
the presence of more than one plasmacytoma (occurring 
concurrently or sequentially) in the absence of bone 
marrow evidence of MM. Extramedullary plasmacytoma 
can arise in patients with multiple myeloma (MM) at any 
time during the course of the disease (extramedullary MM, 
EMM) (Swerdlow et al. 2016). 
 SPB accounts for approximately 5% of plasma cell 
malignancies. SEP accounts for approximately 3% of 
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plasma cell malignancies. The median age at diagnosis 
is 55 to 65 years in SPB and 55 to 60 years in SEP. In 
SPB, men are diagnosed twice as frequently as women. 
Approximately two-thirds of patients with SEP are male 
(Dores et al. 2009; Frassica et al. 1989; Shih et al. 1995). 
A little more than half of patients with SPB will eventually 
develop overt MM and SPB had a poorer prognosis than SEP 
(Guo et al. 2013). For patients with SPB, median overall 
survival (OS) was approximately 10 years; 5-year OS rate 
was 75%; 10-year OS rate was 45%; 5-year disease-free 
survival (DFS) rate was 45% and 10-year DFS rate was 25% 
(Frassica et al. 1989). For patients with SEP, the median 
overall survival was 12.5 years; 5-year OS rate was 88% 
and 10-year OS rate was 55% (Creach et al. 2009). Patients 
with SEP involving the head and neck region had superior 
median survival when compared to patients with other 
sites of SEP (13 versus 4 years) (Gerry & Lentsch 2013). 
 Adverse prognostic factors of SP for progression into 
MM are larger tumor size (≥5 cm), serum β2 microglobulin 
>3.5 mg/L, persistence of serum M-protein after radiation 
therapy (Galieni et al. 1995) and SEP with minimal marrow 
involvement. Other reported predictors for progression 
to MM include the presence of osteopenia, reduction in 
uninvolved immunoglobulin levels (Jackson & Scarffe 
1991) and the presence of high-grade angiogenesis in the 
tumor sample (Kumar et al. 2003). 
 The treatment of choice for SEP is radiation therapy, 
given with curative intent at a dose of 40 to 50 Gy over 
four weeks (Creach et al. 2009). For patients with an 
incompletely resected SEP after diagnostic biopsy, local 
radiation therapy is recommended rather than further 
surgery, chemotherapy or observation (Grade 1C). For 
patients with completely resected SEP after diagnostic 
biopsy, observation is recommended rather than adjuvant 
radiation therapy or chemotherapy (Grade 2C) (Soutar 
et al. 2004). The treatment of choice for SPB is localized 
radiation therapy, given at a dose of 40 to 50 Gy over four 
weeks, directed at the tumor site (Grade 1C) (Reed et al. 
2011), whereas the standard treatment for MM is systemic 
therapy. 
 We report an interesting case of solitary plasmacytoma, 
which showed the classical spectrum of plasma cell 
proliferative disorder, i.e., recurrences of plasmacytoma 
and then evolution into multiple plasmacytomas. 
CASE REPORT
In 2003, a 56-year-old man, with hypertension and 
ischemic heart disease, presented with the 5-month-history 
of right nasal obstruction and intermittent epistaxis. 
He had solitary extramedullary plasmacytoma of the 
nasopharynx (3.5 × 2 × 2.5 cm) (Figure 1), with no 
paraproteinaemia. He received radical radiotherapy (56 
Gy) to the nasopharynx, achieving complete remission.
 Ten years later, in 2014, he had recurrence of 
plasmacytoma (osseous) in left tibia (10 × 6 cm) (Figures 
1 & 2), presenting with pathological fracture. There was 
monoclonal paraproteinaemia (4.2 g/L, IgG lambda). 
He received radical radiotherapy (50 Gy) to left tibia, 
achieving partial response. 
 In July 2016, he had recurrence of plasmacytoma 
(osseous) in right tibia (Figure 1), presenting with 
2-month-history of right leg pain and swelling. There 
was presence of monoclonal paraprotein (IgG lambda, 5.5 
g/L in serum and 75 mg/L in urine). He received radical 
radiotherapy (45 Gy) to right tibia. 
 Just after completing radiotherapy to right tibia, in 
November 2016, he presented again with increasing in 
severity of pain in right leg. There was progressive swelling 
in the area around right eye, double vision and headache. 
 On examination, there were proptosis of right eye 
and swelling in right leg. Imaging scans showed multiple 
plasmacytomas at right frontal (5.6 × 4.9 × 5.3 cm) 
(SUV max: 2.7), left frontal (1.1 × 1.4 × 1.4 cm), left 
high frontal, left high posterior parietal, right occipital 
bones, both tibia (SUVmax: right 2.6, left 2.5) and 
hypermetabolic lytic lesions in both 4th metatarsal bones 
(SUVmax: right 2.7, left 2.1). The extra-axial mass at right 
frontal convexity extends inferiorly into the right orbital 
extraconal space causing proptosis of the right eye globe 
and displacement of the superior rectus muscle and the 
optic nerve inferiorly. There was erosion of the adjacent 
right frontal skull vault and orbital plate (Figure 1). The 
rest of the marrow metabolic activity was homogenously 
increased (SUVmax: 3.5). Nasopharynx had normal 
morphometabolic appearance (liver SUVmax: 3.5). Biopsy 
of right tibia showed osseous plasmacytoma (Table 1, 
Figure 2). Monoclonal paraprotein level was increasing 
in trend (IgG lambda, 6.3 g/L in serum and 104.7 mg/L 
FIGURE 1. Imaging showing plasmacytomas
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in urine). There were hypercalcemia (corrected calcium 
2.62 mmol/L) and lytic bone lesions. 
 Bone marrow aspirate result showed 3% plasma 
cells with occasional plasma cells showing abnormal 
morphology such as flame shape and binuclearity. Bone 
marrow trephine sample was suboptimal. Conventional 
cytogenetic analysis of bone marrow sample showed 
normal male chromosome, 46,XY, with no clonal 
abnormality, however, fluorescence in situ hybridization 
(FISH) result was not available. He was treated as MM. 
In 2017, he was 70 years old and had multiple co-
morbidities such as hypertension, ischemic heart disease, 
diabetes mellitus and dyslipidemia. His ECOG (The 
Eastern Cooperative Oncology Group) performance 
status score (Oken et al. 1982) was 2. He was treated with 
Bortezomib-based therapy (Bortezomib-Thalidomide-
Dexamethasone). Currently after one cycle of treatment, 
clinical improvement is achieved (serum paraprotein 4.1 
g/L, urine paraprotein 20 mg/L, no more headache/ double 
vision/ proptosis/ hypercalcaemia) (Table 1). 
DISCUSSION
SEPs are plasma cell tumors that arise outside of the 
bone marrow. Diagnosis of SEP is made based on the 
following features: biopsy-proven extramedullary tumor 
with evidence of clonal plasma cells; no lytic lesions in 
metastatic bone survey and either PET/CT or MRI of the 
spine and pelvis; no clonal plasma cells in bone marrow 
aspirate and biopsy; no anemia, hypercalcemia or renal 
insufficiency that could be attributed to a clonal plasma 
cell proliferative disorder (Rajkumar et al. 2006). The 
first presentation of our patient, i.e. SEP, demonstrated 
the typical presentation of SEP for age, gender and 
presenting symptoms. He received the standard therapy, i.e. 
radiotherapy, achieving complete remission and prolonged 
disease-free survival for 10 years. 
 At initial diagnosis of plasmacytoma, it is important 
to distinguish SP from other plasma cell dyscrasias, 
especially MM, for the purpose of prognosis and treatment. 
Evaluation of a patient with a suspected SP should include 
the full diagnostic work-up of MM, i.e. unilateral bone 
marrow aspiration and biopsy, metastatic bone survey 
and either a PET/CT scan or an MRI of entire spine and 
pelvis, blood investigations such as complete blood 
count and differential with examination of peripheral 
blood smear, serum calcium, creatinine, albumin, lactate 
dehydrogenase, beta-2 microglobulin, and serum and urine 
protein electrophoresis with immunofixation, quantitation 
of immunoglobulins, serum free light chain assay, in 
addition to complete history and physical examination and 
tissue biopsy of the suspected lesion. In our patient, the 
diagnosis of SEP of the nasopharynx was made after the 
proper evaluation to exclude MM. 
 Following the completion of therapy, it is important 
to have regular follow-up at periodic intervals to monitor 
for treatment complications and assess for possible relapse. 
Progression rate of SEP to MM is reported to be between 
11 and 33% over 10 years (Cantone et al. 2017). For our 
patient, even though he achieved complete remission 
from the very first plasmacytoma, he still had been 
regular follow-up with the otorhinolaryngology team 
and haematology team, resulting in early detection and 
timely management of his recurrences of plasmacytomas. 
From literature review, there were similar case reports 
presenting the recurrence of plasmacytoma, highlighting 
the importance of regular long-term follow up to monitor 
the disease recurrence or progression to MM (Chang et al. 
2014; Corvo et al. 2013). 
 The recommendation for the frequency of visit is 
every three months for the first two years, then every six 
months for an additional three years, then yearly or every 
other year after five years. At each visit, the parameters 
to perform for monitoring are history and physical 
examination, urine and serum protein electrophoresis with 
immunofixation, complete blood count, serum creatinine 
and serum calcium. For patients with head and neck 
involvement, a fiberoptic endoscopy is performed at each 
FIGURE 2. Tissue biopsy and histopathological examination (HPE) showing plasmacytomas
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TABLE 1. Clinical characteristics, treatment and outcome of plasmacytomas in the patient
2003 2014 July 2016 November 2016
Presentation 5-month-history of right 
nasal obstruction and 
intermittent epistaxis
Pathological fracture 
(sharp pain over left leg 
upon standing from the 
seat on the bus, then 
unable to walk)
2-month-history of 
right leg pain and 
swelling
 
Increasing in severity of 
pain in right leg. 
2-month-history of 
progressive swelling  in 
the area around right eye. 
double vision, 
headache
Physical examination Nasal endoscopy: a 
friable, dark red mass 
arising from the roof 
of the nasopharynx, 
completely occluding the 
right choana
Tenderness and swelling 
in left leg
Tenderness in right leg Swelling in right leg. 
proptosis of right eye
Imaging CT paranasal sinus - a 
soft tissue mass (3.5 × 2 × 
2.5 cm) in right posterior 
nasal space
MRI leg -pathological 
fracture of left proximal 
tibia secondary to 
plasmacytoma (an well-
defined lesion arising 
from the metadiphyseal 
region of the left tibia,       
10 × 6) with satellite 
lesions at femoral condyle 
and head of fibula
XR (right leg) lytic 
lesion at diaphysis of 
right tibia
MRI brain - multicentric 
skull plasmacytoma 
[right frontal (5.6 × 4.9 × 
5.3 cm), left frontal (1.1 
× 1.4 × 1.4 cm), left high 
frontal, left high posterior 
parietal, right occipital 
bones]
Skeletal survey XR - no 
lytic lesions
PET/CT - active disease in 
left tibia (SUVmax:3.5) 
(liver SUVmax:3.4)
lytic lesion at left frontal 
bone with no increased 
metabolic activity
- PET/CT - hypermetabolic 
extra-axial right frontal 
(SUVmax: 2.7) and 
left frontal lesions. 
hypermetabolic lytic 
lesions at both tibia 
(SUVmax: right 2.6, left 
2.5) and 4th metatarsal 
bones (SUVmax: right 
2.7, left 2.1)
Tissue biopsy and 
histopathological 
examination (HPE)
Biopsy of nasopharyngeal 
mass - extramedullary 
plasmacytoma.
diffuse infiltration 
of plasma cells in 
submucosa; mature, 
eccentric nuclei, clock-
face chromatin pattern.
IHC: lambda restriction
Tru-cut biopsy of left tibia 
- osseous plasmacytoma. 
diffuse infiltration 
of sheets of plasma 
cells; eccentric nuclei, 
perinuclear halo. IHC: 
CD138+, lambda light 
chain restriction. 
ISH: lambda light chain 
restriction
Not performed Biopsy of right tibia 
(bone, tissue) - osseous 
plasmacytoma.
diffuse infiltration 
of neoplastic plasma 
cells; eccentric nuclei, 
perinuclear halo. IHC: 
CD138+, lambda light 
chain restriction
Diagnosis Solitary extramedullary 
plasmacytoma, 
nasopharynx
Solitary osseous 
plasmacytoma,    
left tibia
Solitary osseous 
plasmacytoma,  right 
tibia
Multiple osseous 
plasmacytomas
(both frontal, multicentric 
skull, both tibia)
BMB aspirate 
plasma cell %
3% 3% 4% 3% (occasional plasma 
cells had abnormal 
morphology: flame 
shape, binuclearity)
BMB Trephine Unsatisfactory specimen No evidence of neoplastic 
plasma cell infiltration
No abnormal plasma 
cell infiltration
Suboptimal sample
continue
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visit. If the SEP was measurable by an imaging modality 
prior to therapy, the same modality (e.g. MRI) should be 
repeated three to four months after completing therapy, and 
periodically thereafter. For all patients, CT or CT/PET  or 
MRI (whichever imaging modality was used for the initial 
evaluation) should be performed every 6 to 12 months for 
the first five years after therapy.
 In our case, the patient was found to have multiple 
plasmacytomas involving critical sites and evolving 
into MM. It is crucial to be aware of timely intervention 
for complete diagnostic work-up in order to obtain the 
definitive diagnosis, especially for those with plasmacytoma 
involving critical sites such as eyes and central nervous 
system. Imaging technique like PET/CT scan plays an 
important role in timely detection of plasmacytoma with 
MM. This case report highlights the clinicians not to delay 
definitive treatment when plasmacytomas involves critical 
sites e.g. eyes, orbit, cranial nerves and spinal cord. 
 Bortezomib-based therapy followed by autologous 
haemopoietic stem cell transplantation (HSCT), whenever 
it is possible, is indicated for patients with solitary 
plasmacytoma who progressed into overt MM. For our 
patient, in view of age and multiple comorbidities, he was not 
eligible for HSCT and opted for Bortezomib-based therapy. 
CONCLUSION
The importance of multi-disciplinary approach 
(otorhinolaryngology, radiotherapy and oncology, 
orthopedic, ophthalmology, haematology teams) for 
managing the patients with plasmacytoma is highlighted 
in order to achieve the holistic approach of management 
in terms of: thorough evaluation at presentation to rule 
out MM, choice of appropriate management (radiotherapy 
or systemic therapy) and regular long-term follow-up to 
monitor recurrence of SP or progression into overt MM.
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2003 2014 July 2016 November 2016
Conventional cytogenetic 
analysis
46,XY [20], no clonal 
abnormality
Hypodiploidy (40-45 
chromosomes) in 11 
metaphase spreads 
Not available 46,XY [17], no clonal 
abnormality
FISH Not available Not available Not available Not available
Hypercalcemia
(Normal cCa: 2.10 - 2.55 
mmol/L)
No No No Hypercalcaemia (cCa 
2.62 mmol/L)
Renal insufficiency 
(Normal creatinine: 63.6 
- 110.5 μmol/L)
No No No No 
Anemia
(Normal Hb: 13.5 - 17.4 
g/dL)
No No No No 
SUEP No paraproteinaemia Monoclonal 
paraproteinaemia (IgG 
lambda)
Presence of 
monoclonal 
paraprotein  (IgG 
lambda)
Presence of monoclonal 
paraprotein (IgG lambda)
SPP (g/L) 0 4.2 g/L 5.5 g/L 6.3 g/L 
UPP (mg/L) 0 0 75 mg/L 104.7 mg/L 
Treatment Radical radiotherapy to 
the nasopharynx 
(56 Gy) 
Radical radiotherapy to 
left tibia 
(50 Gy)
Radical radiotherapy 
to right tibia 
(45 Gy)
Bortezomib-based 
therapy (Bortezomib-
Thalidomide-
Dexamethasone) 
(financial constraint)
Thalidomide-based 
therapy (Melphalan-
Prednisolone-
Thalidomide)
Outcome Complete remission Partial metabolic response Progression Clinical improvement 
BMB: bone marrow biopsy, CT: computed tomography, cCa: corrected calcium, FISH: fluorescence in-situ hybridization, Hb: haemoglobin, IHC: immunohistochemistry, 
ISH: in-situ hybridization, MRI: magnetic resonance imaging, PET/CT: positron emission tomography/ computed tomography, SPP: serum paraprotein, SUEP: serum and 
urine protein electrophoresis, SUVmax: maximum standardized uptake value, UPP: urine paraprotein, XR: X-ray
Continued (TABLE 1)
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